# Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00012259** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 31 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** troxacitabine

## Key facts

- **NCT ID:** NCT00012259
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12-11
- **Primary completion:** 2002-03-27
- **Final completion:** 2002-03-27
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00012259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00012259, "Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00012259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*